PTC Therapeutics (NASDAQ:PTCT) Raised to “Strong-Buy” at Wall Street Zen

Posted by Francis Steltz on Sep 21st, 2026

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other research firms have also weighed in on PTCT. Cantor Fitzgerald upped their price objective on PTC Therapeutics from $124.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Jefferies Financial Group upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the company from $76.00 to $85.00 in a report on Wednesday, May 27th. Weiss Ratings cut PTC Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday. Citigroup upgraded PTC Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $75.00 to $108.00 in a report on Tuesday, June 9th. Finally, Morgan Stanley increased their price target on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, PTC Therapeutics has an average rating of “Moderate Buy” and an average target price of $98.50.

Get Our Latest Stock Report on PTC Therapeutics

PTC Therapeutics Stock Performance

Shares of PTCT opened at $65.37 on Friday. PTC Therapeutics has a one year low of $57.74 and a one year high of $90.87. The stock has a market capitalization of $5.46 billion, a price-to-earnings ratio of -112.71, a PEG ratio of 2.02 and a beta of 0.55. The stock has a 50 day moving average price of $72.27 and a 200 day moving average price of $72.14.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.68. The business had revenue of $360.52 million for the quarter, compared to analysts’ expectations of $298.63 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 3.80%.The business’s revenue for the quarter was up 101.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.83) EPS. On average, analysts predict that PTC Therapeutics will post 1.17 earnings per share for the current year.

Insider Transactions at PTC Therapeutics

In other news, CEO Matthew Klein sold 10,292 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total transaction of $705,722.44. Following the completion of the sale, the chief executive officer owned 383,868 shares in the company, valued at approximately $26,321,828.76. This represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Neil Almstead sold 2,464 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $90.25, for a total value of $222,376.00. Following the sale, the insider directly owned 60,299 shares of the company’s stock, valued at $5,441,984.75. The trade was a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 162,669 shares of company stock worth $13,208,674 over the last 90 days. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

Several hedge funds have recently added to or reduced their stakes in PTCT. BlackRock Inc. acquired a new position in shares of PTC Therapeutics in the second quarter worth $1,139,089,000. Jupiter Topco LLC purchased a new stake in PTC Therapeutics during the 2nd quarter worth about $590,182,000. Janus Henderson Group PLC raised its stake in PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after purchasing an additional 2,342,101 shares during the last quarter. William Blair Investment Management LLC purchased a new position in PTC Therapeutics in the 2nd quarter valued at about $140,520,000. Finally, Bank of America Corp DE acquired a new stake in shares of PTC Therapeutics during the 2nd quarter worth about $118,462,000.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. The company uses technologies involving RNA biology, gene therapy and small-molecule drug discovery to address conditions with limited treatment options, including rare neurological and metabolic disorders.

PTC’s commercial portfolio has included Translarna (ataluren), an investigational treatment in some markets for Duchenne muscular dystrophy associated with a nonsense mutation, and Emflaza (deflazacort), a corticosteroid approved in the United States for Duchenne muscular dystrophy.